Tag: Silo Pharma - Psychedelic Alpha

Read more about the article Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA

Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA

Post published:September 20, 2023
Post category:Press Release

Read more about the article Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD

Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD

Post published:September 12, 2023
Post category:Press Release

Read more about the article Silo Pharma Engages Clarivate for Intellectual Property and Patent Management

Silo Pharma Engages Clarivate for Intellectual Property and Patent Management

Post published:August 10, 2023
Post category:Press Release

Read more about the article Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders

Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders

Post published:August 8, 2023
Post category:Press Release

Read more about the article Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent

Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent

Post published:June 21, 2023
Post category:Press Release

Read more about the article Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic

Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic

Post published:June 13, 2023
Post category:Press Release

Read more about the article Silo Pharma Announces Participation on Webull Corporate Communications Service Platform

Silo Pharma Announces Participation on Webull Corporate Communications Service Platform

Post published:June 2, 2023
Post category:Press Release

Read more about the article Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

Post published:May 30, 2023
Post category:Press Release

Read more about the article Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease

Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease

Post published:May 9, 2023
Post category:Press Release

Read more about the article Silo Pharma to Present at Psychedelic Drug Development Conference

Silo Pharma to Present at Psychedelic Drug Development Conference

Post published:April 24, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.